Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Green

Showing results (131-140 of 205) with videos related to

Pageof 21
Sort By:
Cancer Treatment Reports|February 1, 1986
Activity of epirubicin in pancreatic carcinomaH Hochster, M D Green, J L Speyer, et al.
Advances in Experimental Medicine and Biology|January 1, 1986
Effect of suicide substrate on the metabolism of steroids and xenobiotics and on cytochrome P-450 apoproteinsT R Tephly, K A Black, M D Green, et al.
Investigational New Drugs|January 1, 1986
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trialH S Hochster, M D Green, R H Blum, et al.
International Journal of Dermatology|November 1, 1991
Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma. Complexity of objective evaluationM A Oziemski, S P Rockman, D I Marks, et al.
Molecular Pharmacology|January 1, 1986
Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteinsT R Tephly, K A Black, M D Green, et al.
Cancer Treatment Reviews|December 1, 1985
Doxorubicin and interferon: rationale and clinical experienceM D Green, J Speyer, J Wernz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancyR L Basser, M M Sobol, G Duggan, et al.
Nature|November 20, 1980
High-affinity anti-oestrogen binding site distinct from the oestrogen receptorR L Sutherland, L C Murphy, M San Foo, et al.
Cancer Treatment Reports|April 1, 1984
Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancerM D Green, J S Speyer, J C Bottino, et al.
Cancer Treatment Reviews|March 1, 1991
Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reductionJ Koning, P Palmer, C R Franks, et al.
Pageof 21

Showing results (131-140 of 205) with videos related to

Sort By:
Pageof 21
Cancer Treatment Reports|February 1, 1986
Activity of epirubicin in pancreatic carcinomaH Hochster, M D Green, J L Speyer, et al.
Advances in Experimental Medicine and Biology|January 1, 1986
Effect of suicide substrate on the metabolism of steroids and xenobiotics and on cytochrome P-450 apoproteinsT R Tephly, K A Black, M D Green, et al.
Investigational New Drugs|January 1, 1986
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trialH S Hochster, M D Green, R H Blum, et al.
International Journal of Dermatology|November 1, 1991
Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma. Complexity of objective evaluationM A Oziemski, S P Rockman, D I Marks, et al.
Molecular Pharmacology|January 1, 1986
Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteinsT R Tephly, K A Black, M D Green, et al.
Cancer Treatment Reviews|December 1, 1985
Doxorubicin and interferon: rationale and clinical experienceM D Green, J Speyer, J Wernz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancyR L Basser, M M Sobol, G Duggan, et al.
Nature|November 20, 1980
High-affinity anti-oestrogen binding site distinct from the oestrogen receptorR L Sutherland, L C Murphy, M San Foo, et al.
Cancer Treatment Reports|April 1, 1984
Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancerM D Green, J S Speyer, J C Bottino, et al.
Cancer Treatment Reviews|March 1, 1991
Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reductionJ Koning, P Palmer, C R Franks, et al.
Pageof 21